Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Congress Wealth Management LLC DE

Congress Wealth Management LLC DE boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,288 shares of the company’s stock after acquiring an additional 209 shares during the quarter. Congress Wealth Management LLC DE’s holdings in Medpace were worth $4,082,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Summit Creek Advisors LLC boosted its stake in shares of Medpace by 0.3% in the fourth quarter. Summit Creek Advisors LLC now owns 47,808 shares of the company’s stock valued at $15,883,000 after purchasing an additional 146 shares during the period. Vanguard Group Inc. lifted its holdings in Medpace by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock worth $854,087,000 after buying an additional 25,704 shares in the last quarter. LPL Financial LLC boosted its position in Medpace by 5.3% in the 4th quarter. LPL Financial LLC now owns 17,960 shares of the company’s stock valued at $6,010,000 after buying an additional 909 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Medpace during the fourth quarter valued at about $2,093,000. Finally, Virtu Financial LLC increased its position in shares of Medpace by 3.7% during the fourth quarter. Virtu Financial LLC now owns 4,669 shares of the company’s stock worth $1,551,000 after acquiring an additional 167 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MEDP. Robert W. Baird increased their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partners began coverage on shares of Medpace in a report on Monday. They set a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Medpace has a consensus rating of “Hold” and a consensus target price of $376.30.

Medpace Trading Down 1.8 %

NASDAQ:MEDP opened at $324.51 on Wednesday. The company has a 50-day moving average of $337.16 and a 200-day moving average of $339.57. The firm has a market cap of $9.89 billion, a price-to-earnings ratio of 25.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.